RECURRENT GLIOBLASTOMA, IDH-WILDTYPE

This early-stage trial tests a new two-drug combination for people whose glioblastoma (a type of brain cancer) has come back. The drugs, triapine and temozolomide, work by damaging cancer cell DNA to stop tumor growth. The main goal is to find the safest dose and understand side …

This early-stage trial tests if stem cells taken from body fat are safe for people with glioblastoma or astrocytoma that has returned after standard treatment. About 20 adults will receive the cells directly into the brain during surgery. The goal is to find the best dose and see…

This study tests two drugs, GI-102 and pembrolizumab, given before surgery to people whose aggressive brain cancer (glioblastoma) has returned. The goal is to see if these drugs can shrink the tumor and help the immune system fight the cancer. About 36 adults will take part, and …

This study tests two immunotherapy drugs, efineptakin alfa and pembrolizumab, in people whose glioblastoma has returned after standard treatment. The goal is to see if this combination can help the immune system attack the tumor and improve survival. About 54 adults with recurren…

This early-stage trial tests a new treatment for people with high-grade gliomas that have returned or worsened. The therapy uses the patient's own immune cells, modified in a lab to recognize and attack tumor cells, and delivers them directly into the brain. The main goals are to…

This early-phase study tests a combination of two immunotherapy drugs (D2C7-IT and 2141-V11) for people with recurrent glioblastoma, an aggressive brain cancer. The treatment is delivered directly into the brain after surgery, followed by injections near the neck. The goal is to …

This study tests a new treatment called P134 cells, which are specially engineered immune cells (CAR-T cells) designed to target and attack recurrent glioblastoma, a severe type of brain cancer. The trial involves 26 adults whose cancer has returned and who have a specific marker…